Screener
BioCryst Pharmaceuticals BCRX Common Stock Par Value Per Share
Common Stock Par Value Per Share at other companies
Other financials
Where this comes from
Reported directly by BioCryst Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:CommonStockParOrStatedValuePerShare.
The source filing: BioCryst Pharmaceuticals’s 10-Q, filed August 5, 2026.
- Filed
- Aug 5, 2026, 4:04 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001628280-26-053300
| Line item | June 30, 2026 | December 31, 2025 |
|---|---|---|
| Total liabilities | 1,012,140 | 633,311 |
| Stockholders’ deficit: | ||
| Preferred stock, $0.01 par value; shares authorized - 5,000; no shares issued and outstanding at June 30, 2026 and December 31, 2025 | — | — |
| Common stock, $0.01 par value; shares authorized - 450,000; shares issued and outstanding – 255,265 at June 30, 2026 and 213,060 at December 31, 2025 | 2,553 | 2,131 |
| Additional paid-in capital | 1,693,282 | 1,384,857 |
| Accumulated other comprehensive (loss) income | (528) | 38 |
| Accumulated deficit | (2,149,596) | (1,506,179) |
| Total stockholders’ deficit | (454,289) | (119,153) |
Item 1. Financial Statements (Unaudited):
FAQ
- What is BioCryst Pharmaceuticals's common stock par value per share?
- BioCryst Pharmaceuticals (BCRX) reported common stock par value per share of $0.01 in Q2 2026.
- How has BioCryst Pharmaceuticals's common stock par value per share changed year-over-year?
- BioCryst Pharmaceuticals's common stock par value per share decreased by 0.0% year-over-year, from $0.01 to $0.01.
- What is the long-term trend for BioCryst Pharmaceuticals's common stock par value per share?
- Over 3 years (2022 to 2025), BioCryst Pharmaceuticals's common stock par value per share has grown at a 0.0% compound annual growth rate (CAGR), from $0.01 to $0.01.
- What does common stock par value per share mean?
- The par value of common stock is the arbitrary legal value assigned to each share of common stock at the time of issuance. It is a legacy accounting requirement that has little impact on the actual market value or trading price of the shares.
Ask your AI about BioCryst Pharmaceuticals's common stock par value per share.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude